[Broncholytic inhalation therapy. Double-blind study hexoprenaline orziprenaline in chronic obstructive respiratory tract diseases].
D000328:Adult; D000402:Airway Obstruction / Q000628:therapy*; D001982:Bronchial Diseases / Q000628:therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007545:Isoproterenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008297:Male; D009921:Metaproterenol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D012123:Pulmonary Ventilation; D011674:Pulse; D012129:Respiratory Function Tests; D012138:Respiratory Therapy
D001993:Bronchodilator Agents; D009921:Metaproterenol; D007545:Isoproterenol
Beitrag zur beoncholytischen Inhalationsbehandlung. Doppeltblindversuch Hexoprenalin-Orziprenalin bei chronisch-obstruktiven Atemwegerkrankungen